216
Participants
Start Date
November 25, 2020
Primary Completion Date
March 29, 2021
Study Completion Date
June 6, 2021
Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)
The study drug will be administered in two phases: intravenous infusion of study drug for 10 days followed by oral administration of study drug for 75 days. Thus, the total duration of the study therapy is 12 weeks.
Placebo
The placebo comparator will be administered in two phases: intravenous infusion of placebo solution for 10 days followed by oral administration of placebo pills for 75 days. Thus, the total duration of the study therapy is 12 weeks.
Research Center for Eco-safety, Ltd., Saint Petersburg
City Clinical Hospital n.a. V.P.Demikhov, Moscow
City Clinical Hospital n.a.M.E.Zhadkevitch, Moscow
City Clinical Hospital #13 Avtozavodsky district, Nizhny Novgorod
"Astarta Ltd.", Saint Petersburg
"Consultative and diagnostic center with a polyclinic of the Administrative Department of the President of the Russian Federation", Saint Petersburg
Almazov National Medical Research Centre, Saint Petersburg
City General Hospital №2, Saint Petersburg
City Outpatient Clinic #117, Saint Petersburg
City Outpatient Clinic #51, Saint Petersburg
I. P. Pavlov 1st St. Petersburg State Medical University, Saint Petersburg
MEDICA Ltd., Saint Petersburg
North-West State Medical University named after I.I. Mechnikov, Saint Petersburg
"Diabetes medical center", Samara
Saratov State Medical University n.a. V.I.Razumovsky, Saratov
"GBUZ YAO Regional Clinical Hospital", Yaroslavl
POLYSAN Scientific & Technological Pharmaceutical Company
INDUSTRY